BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011-1019. [PMID: 21145828 DOI: 10.1016/j.jhep.2010.08.030] [Cited by in Crossref: 177] [Cited by in F6Publishing: 154] [Article Influence: 16.1] [Reference Citation Analysis]
Number Citing Articles
1 Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011640. [PMID: 28358980 DOI: 10.1002/14651858.CD011640.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
2 Wu SD, Li L, Wang JY. Ursodeoxycholic acid for nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2012;24:1247-1253. [PMID: 22864259 DOI: 10.1097/meg.0b013e3283572ec0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1758] [Article Influence: 228.6] [Reference Citation Analysis]
4 Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:8341-8350. [PMID: 25024593 DOI: 10.3748/wjg.v20.i26.8341] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
5 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kim TH, Eom JS, Lee CG, Yang YM, Lee YS, Kim SG. An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK. Br J Pharmacol 2013;168:1647-61. [PMID: 23145499 DOI: 10.1111/bph.12057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
7 Lee SH, Cheon GJ, Kim HS, Kim YD, Kim SG, Kim YS, Jeong SW, Jang JY, Kim BS. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial]. Korean J Gastroenterol 2014;64:31-9. [PMID: 25073669 DOI: 10.4166/kjg.2014.64.1.31] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Pearlman M, Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014;30:223-237. [PMID: 24717764 DOI: 10.1097/mog.0000000000000060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
9 Serviddio G, Bellanti F, Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med. 2013;65:952-968. [PMID: 23994574 DOI: 10.1016/j.freeradbiomed.2013.08.174] [Cited by in Crossref: 133] [Cited by in F6Publishing: 114] [Article Influence: 16.6] [Reference Citation Analysis]
10 Lisboa QC, Costa SM, Couto CA. Current management of non-alcoholic fatty liver disease. Rev Assoc Med Bras (1992) 2016;62:872-8. [PMID: 28001263 DOI: 10.1590/1806-9282.62.09.872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
11 Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med. 2017;32:213-228. [PMID: 28171717 DOI: 10.3904/kjim.2016.268] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
12 Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Biochim Biophys Acta Mol Cell Biol Lipids 2019;1864:1422-37. [PMID: 31325638 DOI: 10.1016/j.bbalip.2019.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
13 Murakami M, Une N, Nishizawa M, Suzuki S, Ito H, Horiuchi T. Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springerplus. 2013;2:20. [PMID: 23450079 DOI: 10.1186/2193-1801-2-20] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ratziu V, Cadranel JF, Serfaty L, Denis J, Renou C, Delassalle P, Bernhardt C, Perlemuter G. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol. 2012;57:376-383. [PMID: 22521354 DOI: 10.1016/j.jhep.2012.03.019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
15 Yamanashi Y, Takada T, Suzuki H. Bile Acid as Therapeutic Agents. In: Tazuma S, Takikawa H, editors. Bile Acids in Gastroenterology. Tokyo: Springer Japan; 2017. pp. 61-90. [DOI: 10.1007/978-4-431-56062-3_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
17 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:3777-3785. [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 61] [Article Influence: 13.2] [Reference Citation Analysis]
18 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
19 Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. Journal of Hepatology 2018;68:353-61. [DOI: 10.1016/j.jhep.2017.12.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
20 Talebian R, Panahipour L, Gruber R. Ursodeoxycholic acid attenuates the expression of proinflammatory cytokines in periodontal cells. J Periodontol 2020. [PMID: 31960968 DOI: 10.1002/JPER.19-0013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol. 2015;62:S15-24. [PMID: 25920084 DOI: 10.1016/j.jhep.2015.02.039] [Cited by in Crossref: 350] [Cited by in F6Publishing: 295] [Article Influence: 70.0] [Reference Citation Analysis]
22 Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson WH, Liu Y, Gavrilova O, Patterson AD, Gonzalez FJ. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015;6:10166. [PMID: 26670557 DOI: 10.1038/ncomms10166] [Cited by in Crossref: 246] [Cited by in F6Publishing: 230] [Article Influence: 41.0] [Reference Citation Analysis]
23 Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, Sun X, Tong N. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:284-295. [PMID: 28065744 DOI: 10.1016/j.clinre.2016.11.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 9.8] [Reference Citation Analysis]
24 Martínez Soriano B, Güemes A, Pola G, Gonzalo A, Palacios Gasós P, Navarro AC, Martínez-Beamonte R, Osada J, García JJ. Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model. Can J Gastroenterol Hepatol 2020;2020:7315253. [PMID: 32566547 DOI: 10.1155/2020/7315253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Parikh N, Ahmad J. Nonalcoholic fatty liver disease: pharmacologic and surgical options. Gastroenterol Clin North Am 2011;40:541-59. [PMID: 21893273 DOI: 10.1016/j.gtc.2011.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol. 2012;36 Suppl 1:S41-S45. [PMID: 23141893 DOI: 10.1016/s2210-7401(12)70020-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 2.1] [Reference Citation Analysis]
27 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9:321-328. [PMID: 21438811 DOI: 10.1586/erc.11.15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
28 Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2014;12:1724-1730.e5. [DOI: 10.1016/j.cgh.2014.01.040] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
29 Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev 2013;2013:493413. [PMID: 23970949 DOI: 10.1155/2013/493413] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
30 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 10.6] [Reference Citation Analysis]
31 Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol 2011;35:295-302. [PMID: 21440524 DOI: 10.1016/j.clinre.2011.02.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
32 Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47:869-880. [PMID: 24004441 DOI: 10.3109/10715762.2013.837577] [Cited by in Crossref: 158] [Cited by in F6Publishing: 136] [Article Influence: 19.8] [Reference Citation Analysis]
33 Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 2014;18:73-89. [DOI: 10.1016/j.cld.2013.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
34 Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ, Murad MH, Noureddin M. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:616-629.e26. [PMID: 29913275 DOI: 10.1016/j.cgh.2018.06.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 14.7] [Reference Citation Analysis]
35 Malinowski SS, Byrd JS, Bell AM, Wofford MR, Riche DM. Pharmacologic therapy for nonalcoholic fatty liver disease in adults. Pharmacotherapy. 2013;33:223-242. [PMID: 23359475 DOI: 10.1002/phar.1190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
36 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
37 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
38 Li S, Tan HY, Wang N, Hong M, Li L, Cheung F, Feng Y. Substitutes for Bear Bile for the Treatment of Liver Diseases: Research Progress and Future Perspective. Evid Based Complement Alternat Med 2016;2016:4305074. [PMID: 27087822 DOI: 10.1155/2016/4305074] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
39 Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23:7495-7504. [PMID: 29204050 DOI: 10.3748/wjg.v23.i42.7495] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
40 Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. [PMID: 24053454 DOI: 10.1186/1471-230x-13-140] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 7.4] [Reference Citation Analysis]
41 Gozukara I, Dokuyucu R, Özgür T, Özcan O, Pınar N, Kurt RK, Kucur SK, Dolapcioglu K. Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model. Gynecological Endocrinology 2016;32:492-7. [DOI: 10.3109/09513590.2015.1134478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
42 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
43 Cho T, Kim YJ, Paik SS. The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 2012;15:256-265. [PMID: 24010096 DOI: 10.5223/pghn.2012.15.4.256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
44 Smati S, Canivet CM, Boursier J, Cariou B. Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert Opin Investig Drugs 2021;30:813-25. [PMID: 34214406 DOI: 10.1080/13543784.2021.1951701] [Reference Citation Analysis]
45 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 14.7] [Reference Citation Analysis]
46 Gawrieh S, Chalasani N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:338-48. [PMID: 26378648 DOI: 10.1055/s-0035-1562951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
47 Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58. [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011] [Cited by in Crossref: 156] [Cited by in F6Publishing: 137] [Article Influence: 17.3] [Reference Citation Analysis]
48 Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58:155-168. [PMID: 22885388 DOI: 10.1016/j.jhep.2012.08.002] [Cited by in Crossref: 228] [Cited by in F6Publishing: 190] [Article Influence: 25.3] [Reference Citation Analysis]
49 Keely SJ, Steer CJ, Lajczak-McGinley NK. Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases? Am J Physiol Gastrointest Liver Physiol 2019;317:G872-81. [PMID: 31509435 DOI: 10.1152/ajpgi.00163.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012;26:353-357. [PMID: 22720278 DOI: 10.1155/2012/725468] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
51 Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva K, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021;27:959-75. [PMID: 33776366 DOI: 10.3748/wjg.v27.i10.959] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. Adv Exp Med Biol. 2018;1061:19-44. [PMID: 29956204 DOI: 10.1007/978-981-10-8684-7_3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 16.3] [Reference Citation Analysis]
53 Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, Marschall HU, Trauner M. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol. 2015;62:1398-1404. [PMID: 25617503 DOI: 10.1016/j.jhep.2014.12.034] [Cited by in Crossref: 132] [Cited by in F6Publishing: 115] [Article Influence: 22.0] [Reference Citation Analysis]
54 Wu T, Yang M, Xu H, Wang L, Wei H, Ji G. Serum Bile Acid Profiles Improve Clinical Prediction of Nonalcoholic Fatty Liver in T2DM patients. J Proteome Res 2021;20:3814-25. [PMID: 34043368 DOI: 10.1021/acs.jproteome.1c00104] [Reference Citation Analysis]
55 Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018;38 Suppl 1:56-63. [PMID: 29427492 DOI: 10.1111/liv.13676] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
56 Chamulitrat W, Liebisch G, Xu W, Gan-Schreier H, Pathil A, Schmitz G, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes. Mol Pharmacol 2013;84:696-709. [PMID: 23974795 DOI: 10.1124/mol.113.088039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
57 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
58 Long LH, Xue CQ, Shi JF, Dong JN, Wang L. Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-Analysis. Hepat Mon 2015;15:e29052. [PMID: 26300933 DOI: 10.5812/hepatmon.29052v2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet–fed KK-Ay mice. Metabolism 2012;61:944-53. [DOI: 10.1016/j.metabol.2011.10.023] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
60 Kukla M, Kierach R, Skonieczna M, Hudy D, Dąbrowski K, Menżyk T, Derra A, Boroń D, Grabarek BO. Influence of ursodeoxycholic acid therapy on levels of fibroblast growth factor 21, adiponectin and biochemical parameters in intrahepatic cholestasis of pregnancy. Clin Exp Hepatol 2021;7:13-24. [PMID: 34027111 DOI: 10.5114/ceh.2021.104419] [Reference Citation Analysis]
61 Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58:119-125. [PMID: 22902550 DOI: 10.1016/j.jhep.2012.08.008] [Cited by in Crossref: 203] [Cited by in F6Publishing: 189] [Article Influence: 22.6] [Reference Citation Analysis]
62 Mohammed ED, Abdel-Naim AB, Kangpeng J, Jiang R, Wei J, Sun B. The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sci 2021;264:118615. [PMID: 33096115 DOI: 10.1016/j.lfs.2020.118615] [Reference Citation Analysis]
63 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 101] [Article Influence: 21.2] [Reference Citation Analysis]
64 Gu M, Zhang S, Zhao Y, Huang J, Wang Y, Li Y, Fan S, Yang L, Ji G, Tong Q, Huang C. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling. Pharmacol Res 2017;121:22-32. [PMID: 28428116 DOI: 10.1016/j.phrs.2017.04.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
65 Modaresi Esfeh J, Culver D, Plesec T, John B. Clinical presentation and protocol for management of hepatic sarcoidosis. Expert Rev Gastroenterol Hepatol 2015;9:349-58. [PMID: 25473783 DOI: 10.1586/17474124.2015.958468] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
66 Shetty A, Syn W. Current treatment options for nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 2019;35:168-76. [DOI: 10.1097/mog.0000000000000528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
67 Haedrich M, Dufour JF. UDCA for NASH: end of the story? J Hepatol 2011;54:856-8. [PMID: 21145815 DOI: 10.1016/j.jhep.2010.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
68 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
69 Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, Massault PP, Scatton O, Vaillant JC, Morozov VA, Pol S, Lagaye S. Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs. World J Hepatol 2021;13:187-217. [PMID: 33708350 DOI: 10.4254/wjh.v13.i2.187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014;20:8407-15. [PMID: 25024598 DOI: 10.3748/wjg.v20.i26.8407] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
71 Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871. [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044] [Cited by in Crossref: 223] [Cited by in F6Publishing: 193] [Article Influence: 27.9] [Reference Citation Analysis]
72 Bozic MA, Subbarao G, Molleston JP. Pediatric Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2013;28:448-58. [DOI: 10.1177/0884533613489153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
73 Kwan SY, Jiao J, Qi J, Wang Y, Wei P, McCormick JB, Fisher-Hoch SP, Beretta L. Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican-American Population of South Texas. Hepatol Commun. 2020;4:555-568. [PMID: 32258950 DOI: 10.1002/hep4.1490] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
74 Nakajima K. Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol 2012;2012:950693. [PMID: 23304532 DOI: 10.1155/2012/950693] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
75 Zhang Y, Jiang R, Zheng X, Lei S, Huang F, Xie G, Kwee S, Yu H, Farrar C, Sun B, Zhao A, Jia W. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation. Br J Pharmacol 2019;176:2848-63. [PMID: 31077342 DOI: 10.1111/bph.14705] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
76 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
77 Gabbi C, Bertolotti M, Anzivino C, Macchioni D, Del Puppo M, Ricchi M, Carubbi F, Tagliafico E, Romagnoli D, Odoardi MR, Loria P, Losi L, Carulli N. Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Digestive and Liver Disease 2012;44:1018-26. [DOI: 10.1016/j.dld.2012.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
78 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1562] [Article Influence: 494.5] [Reference Citation Analysis]
79 Gariani K, Philippe J, Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab. 2013;39:16-26. [PMID: 23266468 DOI: 10.1016/j.diabet.2012.11.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 7.7] [Reference Citation Analysis]
80 Tomasiewicz K, Flisiak R, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O; Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD). Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018;4:153-7. [PMID: 30324139 DOI: 10.5114/ceh.2018.78118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
81 Ferrell JM, Boehme S, Li F, Chiang JY. Cholesterol 7α-hydroxylase-deficient mice are protected from high-fat/high-cholesterol diet-induced metabolic disorders. J Lipid Res 2016;57:1144-54. [PMID: 27146480 DOI: 10.1194/jlr.M064709] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
82 Lemoinne S, Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr Opin Pharmacol 2019;49:60-70. [PMID: 31590120 DOI: 10.1016/j.coph.2019.09.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
83 Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-82. e1. [PMID: 23727264 DOI: 10.1053/j.gastro.2013.05.042] [Cited by in Crossref: 534] [Cited by in F6Publishing: 481] [Article Influence: 66.8] [Reference Citation Analysis]
84 Tang Y, Zhang J, Li J, Lei X, Xu D, Wang Y, Li C, Li X, Mao Y. Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019;1864:1293-304. [DOI: 10.1016/j.bbalip.2019.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
85 Ozel Coskun BD, Yucesoy M, Gursoy S, Baskol M, Yurci A, Yagbasan A, Doğan S, Baskol G. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2015;27:142-9. [PMID: 25533429 DOI: 10.1097/MEG.0000000000000264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
86 Vajro P, Paolella G, Pierri L, D’Aniello R. Treatment of NASH with ursodeoxycholic acid: pros and cons. More information in children. Clin Res Hepatol Gastroenterol. 2013;37:e93-e94. [PMID: 23562789 DOI: 10.1016/j.clinre.2013.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
88 Takashima S, Ikejima K, Arai K, Yokokawa J, Kon K, Yamashina S, Watanabe S. Glycine prevents metabolic steatohepatitis in diabetic KK-A y mice through modulation of hepatic innate immunity. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016;311:G1105-13. [DOI: 10.1152/ajpgi.00465.2015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
89 Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011;22:479-88. [PMID: 22002020 DOI: 10.1097/MOL.0b013e32834c7cfc] [Cited by in Crossref: 77] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
90 Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013;4:517-24. [PMID: 24843703 DOI: 10.1111/jdi.12107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
91 Gonzalez FJ, Jiang C, Bisson WH, Patterson AD. Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity. J Hepatol 2015;62:1234-6. [PMID: 25747705 DOI: 10.1016/j.jhep.2015.02.043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
92 Oliveira CP, Cotrim HP, Stefano JT, Siqueira ACG, Salgado ALA, Parise ER. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. Arq Gastroenterol 2019;56:184-90. [PMID: 31460584 DOI: 10.1590/S0004-2803.201900000-36] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
93 Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. J Gastroenterol 2016;51:162-72. [PMID: 26190501 DOI: 10.1007/s00535-015-1104-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
94 Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J ClinExpHepatol. 2015;5:51-68. [PMID: 25941433 DOI: 10.1016/j.jceh.2015.02.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 11.5] [Reference Citation Analysis]
95 Shima KR, Ota T, Kato KI, Takeshita Y, Misu H, Kaneko S, Takamura T. Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study. BMJ Open Diabetes Res Care 2018;6:e000469. [PMID: 29607050 DOI: 10.1136/bmjdrc-2017-000469] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
96 Liechti F, Dufour J. Treatment of NASH with ursodeoxycholic acid: Cons. Clinics and Research in Hepatology and Gastroenterology 2012;36:S46-52. [DOI: 10.1016/s2210-7401(12)70021-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
97 Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14. [DOI: 10.1111/apt.12543] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 8.1] [Reference Citation Analysis]
98 Ye HL, Zhang JW, Chen XZ, Wu PB, Chen L, Zhang G. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci 2020;242:117175. [PMID: 31843528 DOI: 10.1016/j.lfs.2019.117175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
99 Lee JM, Gang GT, Kim DK, Kim YD, Koo SH, Lee CH, Choi HS. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. J Biol Chem 2014;289:1079-91. [PMID: 24265317 DOI: 10.1074/jbc.M113.491522] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
100 Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55:1369-1378. [PMID: 22183915 DOI: 10.1002/hep.25531] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
101 Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
102 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 318] [Article Influence: 40.7] [Reference Citation Analysis]
103 Pietu F, Guillaud O, Walter T, Vallin M, Hervieu V, Scoazec JY, Dumortier J. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol 2012;36:146-55. [PMID: 22154224 DOI: 10.1016/j.clinre.2011.10.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
104 Hu J, Hong W, Yao KN, Zhu XH, Chen ZY, Ye L. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway. World J Gastroenterol 2019;25:1492-501. [PMID: 30948912 DOI: 10.3748/wjg.v25.i12.1492] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
105 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
106 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
107 Jia X, Suzuki Y, Naito H, Yetti H, Kitamori K, Hayashi Y, Kaneko R, Nomura M, Yamori Y, Zaitsu K, Kato M, Ishii A, Nakajima T. A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model. Dig Dis Sci 2014;59:1490-501. [PMID: 24448653 DOI: 10.1007/s10620-014-3028-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
108 Parikh P, Ingle M, Patel J, Bhate P, Pandey V, Sawant P. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients. Saudi J Gastroenterol. 2016;22:192-197. [PMID: 27184636 DOI: 10.4103/1319-3767.182451] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
109 Ciećko-Michalska I, Szczepanek M, Tobiasz-Adamczyk B, Mach T. Non-alcoholic fatty liver disease in Poland: how and at what stage is diagnosed, and how is treated. A survey study. Prz Gastroenterol 2019;14:173-7. [PMID: 31649787 DOI: 10.5114/pg.2019.88165] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011;16:713-29. [PMID: 22195605 DOI: 10.1517/14728214.2011.646260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
111 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
112 Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 2017;10:1225-37. [PMID: 28803504 DOI: 10.1080/17512433.2017.1365599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
113 Mahmoud AA, Elshazly SM. Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. PLoS One 2014;9:e106993. [PMID: 25202970 DOI: 10.1371/journal.pone.0106993] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
114 Wang Y, Liu X, Pijut SS, Li J, Horn J, Bradford EM, Leggas M, Barrett TA, Graf GA. The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination. J Lipid Res 2015;56:810-20. [PMID: 25635125 DOI: 10.1194/jlr.M053454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
115 Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 2013;268:132-40. [PMID: 23391614 DOI: 10.1016/j.taap.2013.01.022] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 11.8] [Reference Citation Analysis]
116 Zhang L, Xie C, Nichols RG, Chan SH, Jiang C, Hao R, Smith PB, Cai J, Simons MN, Hatzakis E, Maranas CD, Gonzalez FJ, Patterson AD. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism. mSystems. 2016;1. [PMID: 27822554 DOI: 10.1128/msystems.00070-16] [Cited by in Crossref: 55] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
117 Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809-820. [PMID: 25873078 DOI: 10.1177/1535370215579161] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
118 Ma Z, Wang X, Yin P, Wu R, Zhou L, Xu G, Niu J. Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. Medicine (Baltimore) 2019;98:e16717. [PMID: 31374067 DOI: 10.1097/MD.0000000000016717] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
119 Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
120 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
121 Cremers JP, Drent M, Baughman RP, Wijnen PA, Koek GH. Therapeutic approach of hepatic sarcoidosis. Curr Opin Pulm Med 2012;18:472-82. [PMID: 22617809 DOI: 10.1097/MCP.0b013e3283541626] [Cited by in Crossref: 27] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
122 Wei M, Huang F, Zhao L, Zhang Y, Yang W, Wang S, Li M, Han X, Ge K, Qu C, Rajani C, Xie G, Zheng X, Zhao A, Bian Z, Jia W. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility. EBioMedicine 2020;55:102766. [PMID: 32408110 DOI: 10.1016/j.ebiom.2020.102766] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
123 Corrado RL, Torres DM, Harrison SA. Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 2014;98:55-72. [DOI: 10.1016/j.mcna.2013.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
124 Chen YS, Liu HM, Lee TY. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice. Cells. 2019;8:253. [PMID: 30884843 DOI: 10.3390/cells8030253] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
125 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
126 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
127 Milic S, Štimac D. Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment. Dig Dis 2012;30:158-62. [DOI: 10.1159/000336669] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 13.8] [Reference Citation Analysis]
128 Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44:877-889. [PMID: 27549244 DOI: 10.1111/apt.13770] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
129 Kusaczuk M. Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives. Cells 2019;8:E1471. [PMID: 31757001 DOI: 10.3390/cells8121471] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
130 Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology. 2016;150:1835-1848. [PMID: 26971824 DOI: 10.1053/j.gastro.2016.03.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 10.2] [Reference Citation Analysis]
131 Higuera-de la Tijera F, Servín-Caamaño AI. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol. 2015;7:1297-1301. [PMID: 26052375 DOI: 10.4254/wjh.v7.i10.1297] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
132 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
133 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
134 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123:1887-1901. [PMID: 23635787 DOI: 10.1172/jci66028] [Cited by in Crossref: 393] [Cited by in F6Publishing: 216] [Article Influence: 49.1] [Reference Citation Analysis]
135 Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Semin Liver Dis. 2015;35:184-198. [PMID: 25974903 DOI: 10.1055/s-0035-1550055] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
136 Schuppan D. Liver fibrosis: Common mechanisms and antifibrotic therapies. Clinics and Research in Hepatology and Gastroenterology 2015;39:S51-9. [DOI: 10.1016/j.clinre.2015.05.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 11.0] [Reference Citation Analysis]
137 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 218] [Article Influence: 27.2] [Reference Citation Analysis]
138 Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 2014;5:21. [PMID: 25937854 DOI: 10.1186/1878-5085-5-21] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
139 Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatol Commun 2021;5:938-46. [PMID: 34141981 DOI: 10.1002/hep4.1689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Yoon S, Lee H, Ji SC, Yoon SH, Cho JY, Chung JY. Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function. Clin Pharmacol Drug Dev 2021;10:68-77. [PMID: 32191400 DOI: 10.1002/cpdd.790] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol 2019;4:781-93. [PMID: 31345778 DOI: 10.1016/S2468-1253(19)30184-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 10.5] [Reference Citation Analysis]
142 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 947] [Article Influence: 119.8] [Reference Citation Analysis]
143 Bourgi K, Wanjalla C, Koethe JR. Inflammation and Metabolic Complications in HIV. Curr HIV/AIDS Rep 2018;15:371-81. [PMID: 30058057 DOI: 10.1007/s11904-018-0411-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
144 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20:12956-12980. [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 83] [Article Influence: 17.3] [Reference Citation Analysis]
145 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
146 Kwok RM, Torres DM, Harrison SA. Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?: Hepatology. Hepatology 2013;58:1166-74. [DOI: 10.1002/hep.26390] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 11.0] [Reference Citation Analysis]
147 Ahadi S, Gharekhani A, Shiva A. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology 2019;20:189-97. [DOI: 10.1016/j.ajg.2019.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Sánchez-García A, Sahebkar A, Simental-Mendía M, Simental-Mendía LE. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res 2018;135:144-9. [PMID: 30099154 DOI: 10.1016/j.phrs.2018.08.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
149 Vítek L. Bile Acids in the Treatment of Cardiometabolic Diseases. Ann Hepatol 2017;16:s43-52. [PMID: 29080341 DOI: 10.5604/01.3001.0010.5496] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
150 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 50] [Article Influence: 20.3] [Reference Citation Analysis]
151 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
152 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 133] [Article Influence: 19.9] [Reference Citation Analysis]
153 Strange RC, Shipman KE, Ramachandran S. Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes. 2015;6:896-911. [PMID: 26185598 DOI: 10.4239/wjd.v6.i7.896] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 50] [Article Influence: 12.8] [Reference Citation Analysis]
154 Paredes AH, Torres DM, Harrison SA. Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2012;16:397-419. [DOI: 10.1016/j.cld.2012.03.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]